Myelodysplastic syndrome occurring after enfortumab vedotin treatment for metastatic urothelial carcinoma.

This is the first report of the development of myelodysplastic syndrome during enfortumab vedotin therapy in a clinical setting. Although rare, myelodysplastic syndrome can occur during enfortumab vedotin therapy.